title: [Osteoporosis: diagnosis, prevention and treatment].
abstract: The paper describes prevalence, mechanisms of development, clinical features of osteoporosis, its complications and the principles of treatment. It includes an overview of the universally accepted diagnostic methods and criteria and discusses the diagnostic value of laboratory and instrumental investigations. The significance of radiological methods of the diagnosis is emphasized with regard to the problems related to differential diagnosis and appropriate evaluation of the risk factors for osteoporosis and fractures. Contemporary methods of both, prevention and treatment of osteoporosis, depending on the bone mineral density and risk factors for osteoporosis, are presented. Possible problems of tolerance and common adverse drug reactions are discussed.
authors.affiliation: Kauno medicinos universiteto Reumatologijos klinika, Eiveniu 2, 3007 Kaunas. astai@centras.lt
authors.forename: Asta
authors.initials: A
authors.lastname: Baranauskaite
authors.forename: Asta
authors.initials: A
authors.lastname: Savickiene
mesh_terms: D000328:Adult; D000368:Aged; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000627:therapeutic use; D000068296:Risedronic Acid; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D002121:Calcium Channel Blockers; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid